Literature DB >> 28040286

Balloon dilatation and outcome among patients undergoing trans-femoral aortic valve replacement.

Noam Fink1, Amit Segev1, Ran Kornowski2, Ariel Finkelstein3, Abid Assali2, Zach Rozenbaum3, Hana Vaknin-Assa2, Amir Halkin3, Paul Fefer1, Jeremy Ben-Shoshan3, Ehud Regev1, Maayan Konigstein3, Katia Orvin2, Victor Guetta1, Israel M Barbash4.   

Abstract

BACKGROUND: Balloon pre-dilatation before transcatheter aortic valve replacement (TAVR) is performed at the discretion of the treating physician. Clinical data assessing the implications of this step on procedural outcomes are limited.
METHODS: We conducted a retrospective analysis of 1164 consecutive TAVR patients in the Israeli multicenter TAVR registry (Sheba, Rabin, and Tel Aviv Medical Centers) between the years 2008 and 2014. Patients were divided to those who underwent balloon pre-dilation (n=1026) versus those who did not (n=138).
RESULTS: Rates of balloon pre-dilation decreased from 95% in 2008-2011 to 59% in 2014 (p for trend=0.002). Baseline characteristics between groups were similar except for more smoking (22% vs. 8%, p=0.008), less past CABG (18% vs. 26%, p=0.016), less diabetes mellitus (35% vs. 45%, p=0.01), and lower STS mortality scores (5.2±3.7 vs. 6.1±3.5, p=0.006) in the pre-dilatation group. The pre-dilation group included less patients with moderate to severely depressed LVEF (7% vs. 16%, p<0.001) and higher aortic peak gradients (76.9±22.7mmHg vs. 71.4±24.3mmHg, p=0.01). Stroke rates were comparable in both groups (2.5% vs. 3%, p=0.8), but pre-dilation was associated with lower rates of balloon post-dilatation (9% vs. 26%, p<0.001). On multivariate analysis, balloon pre-dilatation was not a predictor of device success or any post-procedural complications (p=0.07).
CONCLUSIONS: Balloon pre-dilatation was not associated with procedural adverse events and may decrease the need for balloon post-dilatation. The results of the present study support the current practice to perform liberally balloon pre-dilatation prior to valve implantation.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Balloon dilatation; Complications; Transcatheter aortic valve replacement

Mesh:

Year:  2016        PMID: 28040286     DOI: 10.1016/j.ijcard.2016.12.062

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

Review 1.  Pre-implantation balloon-aortic valvuloplasty before transcatheter aortic valve implantation: is this still needed?

Authors:  Rafail A Kotronias; Michael Teitelbaum; Rodrigo Bagur
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

2.  Balloon-expandable transcatheter aortic valve implantation with or without pre-dilation - results of a meta-analysis of 3 multicenter registries.

Authors:  Jannik Ole Ashauer; Nikolaos Bonaros; Markus Kofler; Gerhard Schymik; Christian Butter; Mauro Romano; Vinayak Bapat; Justus Strauch; Holger Schröfel; Andreas Busjahn; Cornelia Deutsch; Peter Bramlage; Jana Kurucova; Martin Thoenes; Stephan Baldus; Tanja K Rudolph
Journal:  BMC Cardiovasc Disord       Date:  2019-07-19       Impact factor: 2.298

3.  Clinical Predictors for Procedural Stroke and Implications for Embolic Protection Devices during TAVR: Results from the Multicenter Transcatheter Aortic Valve Replacement In-Hospital Stroke (TASK) Study.

Authors:  Anat Berkovitch; Amit Segev; Elad Maor; Alexander Sedaghat; Ariel Finkelstein; Matteo Saccocci; Ran Kornowski; Azeem Latib; Jose M De La Torre Hernandez; Lars Søndergaard; Darren Mylotte; Niels Van Royen; Azfar G Zaman; Pierre Robert; Jan-Malte Sinning; Arie Steinvil; Francesco Maisano; Katia Orvin; Gianmarco Iannopollo; Dae-Hyun Lee; Ole De Backer; Federico Mercanti; Kees van der Wulp; Joy Shome; Didier Tchétché; Israel M Barbash
Journal:  J Pers Med       Date:  2022-06-28

4.  Insights into permanent pacemaker implantation following TAVR in a real-world cohort.

Authors:  Tobias Tichelbäcker; Leonard Bergau; Miriam Puls; Tim Friede; Tobias Mütze; Lars Siegfried Maier; Norbert Frey; Gerd Hasenfuß; Markus Zabel; Claudius Jacobshagen; Samuel Sossalla
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.